GLOBAL DIABETES DRUG MARKET WORTH USD 44.55 BILLION BY 2024

Mourya
Mourya
The report "GLOBAL DIABETES DRUG MARKET”: Segmentation By Drugs(Insulin Derivatives and Oral Diabetic Medication Drugs) By Geography (Asia Pacific, North America, Europe, Middle East And Africa, South America), By Company Profile, Forecast (USD billion) and Estimation 2018-2024.The Global Diabetes Drug market size was estimated at USD 30.98 Billion in 2017 and is expected to reach 44.55 Billion by 2024 at a CAGR of 7.7%.The Diabetes drug market overview shows that diabetes is termed as the mother of all diseases that occurs if sufficient insulin is not produced by the beta cells in the pancreas. Diabetes drugs are used to treat diabetes mellitus by lowering the glucose levels in the blood. The insulin segment accounts for the largest diabetes drug market share owing to its high price and need and demand insulin and is anticipated to hold the highest share owing to the increasing geriatric population and high per capita income.The Glucagon-like peptide-1 (GLP-1) agonist is anticipated to grow during the forecast period owing to rising prevalence of diabetes all over the world.Dipeptidyl-peptidase-4 (DPP-4) inhibitors held second large market share. Based on global diabetes drug market analysis, on the basis of disease type, type 2 diabetes has accounted for the highest market share owing to the increasing disposable income and rising prevalence of obesity. Type 1 diabetes held the second large market share because of the increasing environmental damage. Download a free sample report @ https://www.envisioninteligence.com/industry-report/diabetes-drug-market/ On the basis of geography, North America holds the largest diabetes drug market share owing to the high prevalence of diabetes in this region. Europe is anticipated to hold the second large market share owing to the increased investment in research and development and promising pipeline of diabetes in this region. The Asia Pacific is expected to show the highest diabetes drug market growth rate owing to the increasing awareness and promotion in this region. With the increasing incidence of diabetes, the diabetes drug company’s market shares will increase owing to increasing R&D coupled with aggressive reacting in emerging market. U.S. diabetes drug market represents the presence of more than 27 million diabetes patients owing to the increasing obesity levels and rising geriatric population. Because of the rising incidences of diabetes and the fact that the U.S. has one of the highest per capita healthcare expenditures, the U.S. market for diabetes is expected to grow with a CAGR of XX%. It has been found in the report that more than half of the US population is either obese or overweight which is mainly owing to their sedentary lifestyles, physical in activities and unhealthy eating habits. Diabetes drug market analysis estimates that nearly 65 million are currently affected by diabetes in India. The Indian population had faced undernutrition for a long time is now exposed to overnutrition and sedentary lifestyles. Coupled with a bad nutritional history and the fact that Indians are genetically more vulnerable to diabetes compared to other population groups, India’s struggle with diabetes is expected to be one of the biggest epidemics the country witnessed during the forecast period. These factors are expected to push the diabetes drug market in India in terms revenue. Sinopec, Pasupati Acrylon Ltd., Mitsubishi Rayon Group, Merck & Co, Kaneka Corporation, Kaltex Fibers and some others are the major key players in the global diabetes drug market.